Abstract
The pharmacokinetics (PK) of isepamicin, a new aminoglycoside, were studied in 85 intensive care unit (ICU) patients and were compared with those observed in 10 healthy volunteers. A parametric method based on a nonlinear mixed-effect model was used to assess population PK. Isepamicin was given intravenously over 0.5 h at dosages of 15 mg/kg once daily or 7.5 mg/kg twice daily. The data were fitted to a bicompartmental open model. Compared with healthy volunteers, the mean values of the PK parameters were profoundly modified in ICU patients: elimination clearance was reduced by 48%, the volume of distribution in the central compartment (Vc) was increased by 50%, the peripheral volume of distribution was 70% higher, the distribution clearance was 146% lower, and the elimination half-life was ca. 3.4 times higher. The interindividual variability in PK parameters was about 50% in ICU patients. Five covariates (body weight [BW], simplified acute physiology score [SAPS], temperature, serum creatinine level, and creatinine clearance [CLCR]) were tentatively correlated with PK parameters by multivariate linear regression analysis with stepwise addition and deletion. The variability of isepamicin clearance was explained by three covariates (BW, SAPS, and CLCR), that of Vc was explained by BW and SAPS, and that of the elimination half-life was explained by CLCR and SAPS. Simulation of the concentration-versus-time profile for 500 individuals showed that the mean peak (0.75 h) concentration was 18% lower in ICU patients than in healthy volunteers and that the range in ICU patients was very broad (28.4 to 95.4 mg/liter). Therefore, monitoring of the isepamicin concentration is in ICU patients is mandatory.
Full Text
The Full Text of this article is available as a PDF (183.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chelluri L., Jastremski M. S. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med. 1987 Dec;15(12):1143–1145. doi: 10.1097/00003246-198712000-00015. [DOI] [PubMed] [Google Scholar]
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- Fuhs D. W., Mann H. J., Kubajak C. A., Cerra F. B. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients. Clin Pharm. 1988 Mar;7(3):207–213. [PubMed] [Google Scholar]
- Grevel J., Whiting B., Kelman A. W., Taylor W. B., Bateman D. N. Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. Clin Pharmacokinet. 1988 Jan;14(1):52–63. doi: 10.2165/00003088-198814010-00004. [DOI] [PubMed] [Google Scholar]
- Halstenson C. E., Kelloway J. S., Affrime M. B., Lin C. C., Teal M. A., Shapiro B. E., Awni W. M. Isepamicin disposition in subjects with various degrees of renal function. Antimicrob Agents Chemother. 1991 Nov;35(11):2382–2387. doi: 10.1128/aac.35.11.2382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Halstenson C. E., Wong M. O., Herman C. S., Heim-Duthoy K. L., Teal M. A., Affrime M. B., Kelloway J. H., Keane W. F., Awni W. M. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease. Antimicrob Agents Chemother. 1992 Sep;36(9):1832–1836. doi: 10.1128/aac.36.9.1832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lortholary O., Tod M., Cohen Y., Petitjean O. Aminoglycosides. Med Clin North Am. 1995 Jul;79(4):761–787. doi: 10.1016/s0025-7125(16)30038-4. [DOI] [PubMed] [Google Scholar]
- Maitre P. O., Bührer M., Thomson D., Stanski D. R. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991 Aug;19(4):377–384. doi: 10.1007/BF01061662. [DOI] [PubMed] [Google Scholar]
- Maloney J. A., Awni W. M. High-performance liquid chromatographic determination of isepamicin in plasma, urine and dialysate. J Chromatogr. 1990 Apr 6;526(2):487–496. doi: 10.1016/s0378-4347(00)82530-x. [DOI] [PubMed] [Google Scholar]
- Mann H. J., Fuhs D. W., Awang R., Ndemo F. A., Cerra F. B. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm. 1987 Feb;6(2):148–153. [PubMed] [Google Scholar]
- Marik P. E. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993 Apr;21(2):172–173. doi: 10.1177/0310057X9302100206. [DOI] [PubMed] [Google Scholar]
- Mentré F., Gomeni R. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat. 1995 Jul;5(2):141–158. doi: 10.1080/10543409508835104. [DOI] [PubMed] [Google Scholar]
- Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
- Uematsu T. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. Int J Clin Pharmacol Ther Toxicol. 1993 Dec;31(12):606–610. [PubMed] [Google Scholar]
- Watling S. M., Dasta J. F. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother. 1993 Mar;27(3):351–357. doi: 10.1177/106002809302700319. [DOI] [PubMed] [Google Scholar]